The Second Department of Internal Medicine, University of Toyama, 2630 Sugitani Toyama, Toyama 930-0194, Japan.
Medicina (Kaunas). 2022 Feb 18;58(2):312. doi: 10.3390/medicina58020312.
Cancer therapeutics-related cardiac dysfunction is currently of great concern as one of the pivotal therapeutic targets of onco-cardiology. Only a few studies have reported the occurrence of heart failure following the administration of osimertinib, a third-generation epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor for EGFR mutation-positive advanced non-small cell lung cancer. We report on a 74-year-old woman with osimertinib-induced advanced heart failure with reduced ejection fraction, which was treated by the temporal termination of osimertinib and neurohormonal blocker therapy, as well as heart rate modulation therapy using ivabradine. Despite osimertinib-induced heart failure being relatively rare, aggressive neurohormonal blocker therapy using ivabradine if applicable, as well as the temporal termination of osimertinib, might be a promising therapeutic strategy.
癌症治疗相关的心脏功能障碍目前是肿瘤心脏病学的主要治疗靶点之一，受到极大关注。只有少数研究报告了第三代表皮生长因子受体（EGFR）-酪氨酸激酶抑制剂奥希替尼治疗 EGFR 突变阳性晚期非小细胞肺癌后发生心力衰竭。我们报告了一例 74 岁女性因奥希替尼引起的射血分数降低性晚期心力衰竭，通过暂时停止奥希替尼和神经激素阻滞剂治疗，以及使用伊伐布雷定进行心率调节治疗。尽管奥希替尼引起的心力衰竭相对罕见，但如果适用，使用伊伐布雷定进行积极的神经激素阻滞剂治疗，以及暂时停止奥希替尼治疗，可能是一种有前途的治疗策略。
